What is Texcell?
Texcell operates at the forefront of biopharmaceutical safety, providing essential services for virus safety assessment and viral clearance studies. Their expertise spans custom cell culture, cell banking, and a comprehensive suite of in vitro and in vivo bioassays. By partnering with clients, Texcell enables the confident progression of therapeutic products through development and to market, upholding rigorous biosafety standards. The company's mission is intrinsically linked to safeguarding patient health globally through its specialized biosafety services.
How much funding has Texcell raised?
Texcell has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Texcell
PPP
Public-Private Partnership
What's next for Texcell?
The recent large-scale, late-stage funding signifies a pivotal moment for Texcell, indicating a strong market validation and readiness for accelerated growth. This strategic investment is expected to fuel the expansion of their service offerings, enhance technological infrastructure, and potentially broaden their global reach. As the biopharmaceutical industry continues to innovate with complex biologics and novel cell and gene therapies, Texcell's role in ensuring regulatory compliance and patient safety becomes increasingly vital, positioning them for sustained development and market leadership.
See full Texcell company page
